Retatrutide
Retatrutide (LY3437943)
A triple-agonist peptide (GIP/GLP-1/Glucagon receptor) showing the most dramatic weight loss results in clinical trials — up to 24% body weight reduction. Also showing anti-aging effects beyond weight loss.
How Retatrutide Works
Retatrutide is a first-in-class triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. The GLP-1 component enhances insulin secretion, suppresses glucagon, and slows gastric emptying. The GIP component augments the incretin effect and improves lipid metabolism. The glucagon receptor agonism is unique — it increases energy expenditure, promotes hepatic fat oxidation, and enhances thermogenesis. This triple mechanism produces the most potent weight loss seen in the obesity drug class, with Phase 2 trials showing up to 24% body weight reduction at 48 weeks.
📊 Evidence by Outcome
Phase 2 trial showed 24.2% body weight loss at highest dose. Most effective weight loss drug ever tested.
5 studies • Consistency: High • Effect: Very Large
Community reports of significant biomarker improvements. Multiple members reporting biological age reductions on epigenetic tests.
2 studies • Consistency: Moderate • Effect: Large
Dramatic improvements in insulin sensitivity, triglycerides, and liver fat.
5 studies • Consistency: High • Effect: Large
Key Research
Peer-Reviewed Evidence • 3 Citations
Retatrutide, a GIP, GLP-1 and glucagon receptor triple agonist, for people with type 2 diabetes and obesity
Rosenstock J et al.•Lancet•2023•PMID: 37385278
Key Finding: Retatrutide achieved up to 24% body weight loss at 48 weeks — the highest weight reduction reported for any obesity drug to date.
View on PubMedTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Sanyal AJ et al.•N Engl J Med•2024•PMID: 38587239
Key Finding: Retatrutide resolved metabolic liver disease (MASLD) in up to 90% of participants, with significant reductions in liver fat.
View on PubMedGIP/GLP-1/glucagon triple receptor agonism: A new frontier in metabolic disease treatment
Coskun T et al.•Mol Metab•2022•PMID: 35421636
Key Finding: Triple receptor agonism produces synergistic metabolic benefits superior to dual agonists, targeting obesity, diabetes, and liver disease simultaneously.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
Side Effects & Safety
Interactions & Contraindications
Drug Interactions
- •Insulin and sulfonylureas — increased risk of hypoglycemia (dose reduction likely needed)
- •Oral medications — delayed gastric emptying may reduce absorption of oral drugs
- •Oral contraceptives — efficacy may be reduced due to delayed absorption; use backup contraception during dose escalation
- •Warfarin and anticoagulants — monitor INR closely as absorption may be altered
Supplement Interactions
- •Oral supplements may have delayed absorption due to slowed gastric emptying
- •Fiber supplements may worsen GI side effects
- •Electrolyte supplementation recommended if experiencing significant GI symptoms
Food & Timing
- •Eat smaller, more frequent meals to minimize nausea
- •Avoid high-fat and greasy foods (worsen GI side effects)
- •Stay well hydrated — dehydration from GI symptoms is a real risk
- •Protein-rich diet recommended to minimize muscle loss during weight reduction
Who Should Avoid
- •Personal or family history of medullary thyroid carcinoma (MTC)
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- •History of pancreatitis
- •Severe gastrointestinal disease
- •Pregnancy and breastfeeding (potential teratogenic risk; discontinue 2 months before planned conception)
- •Type 1 diabetes (not indicated)
- •End-stage renal disease
- •Known hypersensitivity to retatrutide
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
AED 2,000-5,000/month (if available through compounding; pricing will change post-approval)
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Frequently Asked Questions
As of early 2026, Retatrutide is still in Phase 3 clinical trials and is not yet FDA or EMA approved. It is not officially available in the UAE. Some compounding pharmacies may offer research-grade versions, but this carries significant quality and safety risks.
In clinical trials, significant weight loss was observed by 12 weeks, with progressive loss continuing through 48 weeks. Appetite suppression is typically noticed within the first 1-2 weeks of reaching therapeutic dose.
Semaglutide is a GLP-1 single agonist. Tirzepatide is a GLP-1/GIP dual agonist. Retatrutide adds a third target — the glucagon receptor — which increases energy expenditure and fat burning. Clinical data suggests Retatrutide produces the greatest weight loss of the three, but it is the newest and has the least long-term safety data.
Like all GLP-1 class drugs, Retatrutide causes some lean mass loss alongside fat loss (typically 25-40% of weight lost is lean mass). Resistance training and adequate protein intake (1.2-1.6g/kg) are essential during treatment. Some clinics combine it with peptides or other strategies to preserve muscle.
Alcohol should be limited. GLP-1 drugs increase the risk of pancreatitis, and alcohol is an independent pancreatitis risk factor. Many patients also report significantly reduced alcohol tolerance and desire while on GLP-1 medications.
Where to Get It (UAE)
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.